In 1991, 117 patients with anemia related to chronic renal failure not yet requiring dialysis were randomized to receive erythropoietin to correct anemia (hematocrit of 40% for males, 35% for females) versus placebo. The gene discussed is EPO; the disease is chronic kidney disease.